JP2017503005A - 敗血症を処置するための方法および組成物 - Google Patents

敗血症を処置するための方法および組成物 Download PDF

Info

Publication number
JP2017503005A
JP2017503005A JP2016553262A JP2016553262A JP2017503005A JP 2017503005 A JP2017503005 A JP 2017503005A JP 2016553262 A JP2016553262 A JP 2016553262A JP 2016553262 A JP2016553262 A JP 2016553262A JP 2017503005 A JP2017503005 A JP 2017503005A
Authority
JP
Japan
Prior art keywords
composition
pleconaril
oil
administration
sepsis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016553262A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017503005A5 (enExample
Inventor
グマステ、アナンド
エー バイロン、デイビッド
エー バイロン、デイビッド
Original Assignee
アンチウイルス セラピューティクス
アンチウイルス セラピューティクス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンチウイルス セラピューティクス, アンチウイルス セラピューティクス filed Critical アンチウイルス セラピューティクス
Publication of JP2017503005A publication Critical patent/JP2017503005A/ja
Publication of JP2017503005A5 publication Critical patent/JP2017503005A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2016553262A 2013-11-08 2014-11-10 敗血症を処置するための方法および組成物 Pending JP2017503005A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361901656P 2013-11-08 2013-11-08
US61/901,656 2013-11-08
US201462061391P 2014-10-08 2014-10-08
US62/061,391 2014-10-08
PCT/US2014/064883 WO2015070181A1 (en) 2013-11-08 2014-11-10 Methods and compositions for treating sepsis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019163255A Division JP2020002167A (ja) 2013-11-08 2019-09-06 敗血症を処置するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2017503005A true JP2017503005A (ja) 2017-01-26
JP2017503005A5 JP2017503005A5 (enExample) 2017-03-02

Family

ID=53042211

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016553262A Pending JP2017503005A (ja) 2013-11-08 2014-11-10 敗血症を処置するための方法および組成物
JP2019163255A Pending JP2020002167A (ja) 2013-11-08 2019-09-06 敗血症を処置するための方法および組成物
JP2022001260A Pending JP2022050545A (ja) 2013-11-08 2022-01-06 敗血症を処置するための方法および組成物
JP2024030212A Pending JP2024063137A (ja) 2013-11-08 2024-02-29 敗血症を処置するための方法および組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019163255A Pending JP2020002167A (ja) 2013-11-08 2019-09-06 敗血症を処置するための方法および組成物
JP2022001260A Pending JP2022050545A (ja) 2013-11-08 2022-01-06 敗血症を処置するための方法および組成物
JP2024030212A Pending JP2024063137A (ja) 2013-11-08 2024-02-29 敗血症を処置するための方法および組成物

Country Status (4)

Country Link
US (4) US20160271113A1 (enExample)
EP (2) EP4241771A3 (enExample)
JP (4) JP2017503005A (enExample)
WO (1) WO2015070181A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022050545A (ja) * 2013-11-08 2022-03-30 アンチウイルス セラピューティクス 敗血症を処置するための方法および組成物

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107616131A (zh) * 2017-09-05 2018-01-23 宁风廷 一种用中草药养猪的方法
WO2020263151A1 (en) * 2019-06-28 2020-12-30 Niklovir Ab Novel antiviral therapies
JP7505160B2 (ja) * 2020-02-14 2024-06-25 バイオノックス インコーポレイテッド ヒドロキシ尿素を含む炎症反応を阻害するための医薬組成物
KR102216319B1 (ko) * 2020-04-10 2021-02-18 주식회사 바이오녹스 히드록시유레아를 포함하는 전신성 염증 억제용 약학 조성물 및 이의 제형
CN111202723A (zh) * 2020-02-15 2020-05-29 江苏艾立康药业股份有限公司 一种达芦那韦吸入干粉药物组合物及其制备方法
CN111888355A (zh) * 2020-08-24 2020-11-06 南开大学 盐酸阿比朵尔在制备用于治疗脓毒症疾病的药物中的应用
CN114983946A (zh) * 2022-06-13 2022-09-02 江苏涟水制药有限公司 一种盐酸阿比多尔颗粒组合物及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009526062A (ja) * 2006-02-09 2009-07-16 シェーリング コーポレイション 薬学的処方物
US7585884B2 (en) * 2001-08-29 2009-09-08 Viropharma Incorporated Oxadiazolyl-phenoxyalkylisoxazoles, compositions thereof and methods for their use as anti-picornaviral agents
US20110237686A1 (en) * 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
WO2012103038A2 (en) * 2011-01-24 2012-08-02 Anterios, Inc. Nanoparticle compositions, formulations thereof, and uses therefor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007001561A (es) 2004-08-04 2007-04-16 Schering Corp Formulacion farmaceutica que comprende pleconaril para tratamiento de enfermedades de vias aereas.
US20070202055A1 (en) * 2006-02-09 2007-08-30 Julianne Berry Pharmaceutical Formulations
AR059359A1 (es) * 2006-02-09 2008-03-26 Schering Corp Formulaciones farmaceuticas que contienen pleconaril
TW201016215A (en) 2008-07-17 2010-05-01 Schering Corp Compositions and uses of antiviral active pharmaceutical agents
US20110195030A1 (en) * 2008-10-15 2011-08-11 The University Of North Carolina At Chapel Hill Nanoparticle compositions comprising liquid oil cores
EP3033080A4 (en) 2013-08-15 2017-01-11 Antivirus Therapeutics Methods and compositions for increasing the effectiveness of antiviral agents
EP4241771A3 (en) * 2013-11-08 2023-11-22 Antivirus Therapeutics Methods and compositions for treating sepsis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585884B2 (en) * 2001-08-29 2009-09-08 Viropharma Incorporated Oxadiazolyl-phenoxyalkylisoxazoles, compositions thereof and methods for their use as anti-picornaviral agents
JP2009526062A (ja) * 2006-02-09 2009-07-16 シェーリング コーポレイション 薬学的処方物
US20110237686A1 (en) * 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
WO2012103038A2 (en) * 2011-01-24 2012-08-02 Anterios, Inc. Nanoparticle compositions, formulations thereof, and uses therefor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLINICAL INFECTION DISSEASES, 2001, VOL.32, P.228-235, JPN6018034456, ISSN: 0004025562 *
COLLOIDS AND SURFACES B: BIOINTERFACES, 2013, VOL.105, P.152-157, JPN6018034457, ISSN: 0003872746 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022050545A (ja) * 2013-11-08 2022-03-30 アンチウイルス セラピューティクス 敗血症を処置するための方法および組成物

Also Published As

Publication number Publication date
US20190343811A1 (en) 2019-11-14
US20240245655A1 (en) 2024-07-25
US20210322389A1 (en) 2021-10-21
EP3065550A4 (en) 2018-01-17
EP3065550A1 (en) 2016-09-14
EP4241771A2 (en) 2023-09-13
WO2015070181A1 (en) 2015-05-14
EP4241771A3 (en) 2023-11-22
US20160271113A1 (en) 2016-09-22
JP2020002167A (ja) 2020-01-09
JP2024063137A (ja) 2024-05-10
JP2022050545A (ja) 2022-03-30

Similar Documents

Publication Publication Date Title
JP2022050545A (ja) 敗血症を処置するための方法および組成物
Zhao et al. Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening
KR101868991B1 (ko) 피라졸 유도체 및 그 의약용도
CN101990434B (zh) 用于治疗沙粒病毒感染的抗病毒药物
AU2017325010A1 (en) Mast cell stabilizers for treatment of hypercytokinemia and viral infection
CN107635571A (zh) 含来源于芽孢杆菌属的细菌的细胞外囊泡的治疗妊娠相关疾病的组合物
AU2016287580A1 (en) Compositions and methods for the treatment of viral infection
TW202506136A (zh) 用於治療病毒感染之方法
US11666575B2 (en) Pyrazolo[1,5]pyrimidine-based compounds and methods of their use to treat viral infections
BRPI0618529A2 (pt) meio antiviral, abrangendo zeólitos ativados em forma tribomecánica, própolis e colostro
US20250352527A1 (en) Methods for treating viral infections, organ injury, and related conditions
CN110101703A (zh) Cdk7抑制剂在制备溃疡性结肠炎或结肠癌药物的应用
US20240041861A1 (en) Compositions and methods for treatment and prophylaxis of viral infections
WO2025218456A1 (zh) 巴洛沙韦钠在治疗克里米亚-刚果出血热病毒感染方面的应用
KR20220098175A (ko) B 세포 악성 종양을 치료하기 위한 아칼라브루티닙 및 카피바세르팁의 치료 조합
CN115605193A (zh) 用于治疗SARS-CoV-2感染的半胱胺
EP4126054A1 (en) Methods for treating viral infections with nafamostat
US12427125B2 (en) Method for treating SARS and treating or preventing ARDS
US20230158054A1 (en) Methods, compositions, and dosing regimens for treatment of sars-cov-2 infections
HK40079565A (en) Cysteamine for the treatment of sars-cov-2 infection
Sabiescu et al. COVID-19 in a Pacient with HIV Inflection-A Case Study
TW202539703A (zh) 治療多囊性腎病之方法
WO2025168015A1 (zh) 抗病毒核苷类似物在制备治疗猫冠状病毒药物中的用途
Qiu et al. Analysis on Diagnosis of Family Clustering Infection of SARS-CoV-2
JP2024524631A (ja) 炎症性疾患の治療

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190311

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190507